Enterprise Value
-43.98M
Cash
152M
Avg Qtr Burn
-24.13M
Short % of Float
1.83%
Insider Ownership
26.97%
Institutional Own.
36.22%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KB-0742 (CDK9 Inhibitor) Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
KB-9558 Details Multiple myeloma | Phase 1 Initiation | |
Entospletinib (SYK Inhibitor) Details HOXA9/MEIS1-high AML (Acute myeloid leukemia) | Failed Discontinued | |
Lanraplenib (SYK Inhibitor) +gilteritinib Details Leukemia, Blood cancer, Acute myeloid leukemia, Cancer | Failed Discontinued |